Join Liquidia for a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast from 2:00 p.m. to 4:30 p.m. Eastern Standard Time.

The event will feature presentations from Liquidia’s management team alongside three key opinion leaders (KOLs) in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The agenda will focus on L606 (treprostinil liposome inhalation suspension), an investigational sustained-release formulation, and include a clinical update on its flagship product, YUTREPIA™ (treprostinil) inhalation powder. All presenters will be available to answer questions at the end of the programmed portion of the presentation.

Liquidia’s R&D Day is intended for institutional investors and sell-side analysts.